Robert A. Kyle

Hematology

5716 Cleveland St Ste 200
Virginia Beach, VA 23462

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 480 publications

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology

Published: May 30, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square

Published: April 17, 2026

Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.

Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.

Journal: Blood advances

Published: January 14, 2026

Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis.

Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis.

Journal: Blood advances

Published: January 14, 2026

Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.

Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.

Journal: Leukemia

Published: January 12, 2026

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Journal: Blood advances

Published: November 18, 2025

Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.

Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma.

Journal: Blood cancer journal

Published: October 18, 2025

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

Journal: JACC. CardioOncology

Published: September 16, 2025

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Journal: Blood cancer journal

Published: September 04, 2025

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenström macroglobulinemia.

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenström macroglobulinemia.

Journal: Haematologica

Published: August 28, 2025

Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.

Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.

Journal: Leukemia

Published: July 22, 2025

Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.

Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.

Journal: Blood cancer journal

Published: May 03, 2025

Showing 1-12 of 480

Last Updated: 09/26/2026